Journal · Rheumatology · Updated 21 November 2026
Current Rheumatology Reports
Read Current Rheumatology Reports articles on DeepDyve. No university library needed.
Current Rheumatology Reports has published since 1999 and offers reviews of recent research across rheumatology, from Still’s disease and psoriatic arthritis to osteoarthritis, chronic musculoskeletal pain and axial spondyloarthritis. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Current Rheumatology Reports at a glance
- Full title
- Current Rheumatology Reports
- Abbreviation (NLM)
- Curr Rheumatol Rep
- Publisher
- Springer Nature
- Print ISSN
- 1523-3774
- Online ISSN (eISSN)
- 1534-6307
- First published
- 1999
- Subjects
- Rheumatology
- Access model
- Hybrid (33% free to read in 2026)
Ways to access Current Rheumatology Reports
33% of the articles Current Rheumatology Reports published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 33% of Current Rheumatology Reports articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Current Rheumatology Reports. Check its journal list and whether it offers remote access.
- DeepDyve. Read Current Rheumatology Reports articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Current Rheumatology Reports’ 2025 Journal Impact Factor is 4.9, and its 5-year Impact Factor is 5.7.
4.9
Journal Impact Factor (2025)
5.7
5-year Impact Factor (2025)
5 days
Median time to first decision
Source: journal metrics on the Current Rheumatology Reports homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Current Rheumatology Reports research worth reading
Published January to August 2026. Summaries describe what the authors report.
-
Adipose–Joint Crosstalk in Obesity–Induced Osteoarthritis: Mechanisms, Biomarkers, and Translational Therapeutic Opportunities
The authors review how dysfunctional fat depots drive obesity-induced osteoarthritis through crosstalk among adipocytes, macrophages, fibroblasts and chondrocytes, and point to GLP-1 receptor agonists, anti-adipokine agents and regenerative strategies as promising interventions.
Hang et al. · Current Rheumatology Reports, published online August 8, 2026 · DOI 10.1007/s11926-026-01229-9
-
Type I Interferonopathies: Fifteen Years On, From Concept to Therapeutic Perspectives
Ünal and colleagues review type I interferonopathies, monogenic autoinflammatory diseases caused by inappropriate type I interferon signaling, covering their genetic mechanisms, practical approaches to diagnosis, and current and emerging targeted treatments.
Ünal et al. · Current Rheumatology Reports, published online July 4, 2026 · DOI 10.1007/s11926-026-01228-w
-
Emerging Therapeutics in Rheumatoid Arthritis
Carlson and colleagues review new treatment targets in rheumatoid arthritis, including T-cell pathways such as PD-1 and CD40-CD40L, B-cell therapies such as Bruton’s tyrosine kinase inhibitors, fibroblast-directed drugs, CAR-T cells and bispecific antibodies, noting mixed results so far.
Carlson et al. · Current Rheumatology Reports, published online January 31, 2026 · DOI 10.1007/s11926-025-01209-5
-
Behçet’s Syndrome
Yazici and colleagues summarize what is known about Behçet’s syndrome and recent literature on its diagnosis and management, noting epidemiological studies suggesting it may not be as rare in some areas as thought, along with new treatments and imaging methods.
Yazici et al. · Current Rheumatology Reports, published online March 24, 2026 · DOI 10.1007/s11926-026-01218-y
-
NOD2-Related Multisystem Inflammatory Disorders and Recent Advances
Wu and colleagues review diseases linked to variants in the NOD2 immune sensor gene, including Blau syndrome, Crohn’s disease and Yao syndrome, and describe their own large case-control study confirming the association between certain NOD2 variants and Yao syndrome.
Wu et al. · Current Rheumatology Reports, published online February 12, 2026 · DOI 10.1007/s11926-026-01212-4
Related journals
Questions about Current Rheumatology Reports
How can I read Current Rheumatology Reports articles without a subscription?
33% of Current Rheumatology Reports articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Current Rheumatology Reports articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Current Rheumatology Reports?
Current Rheumatology Reports’ NLM (PubMed) abbreviation is Curr Rheumatol Rep.
What is the ISSN of Current Rheumatology Reports?
The print ISSN is 1523-3774 and the online ISSN is 1534-6307.
What is the impact factor of Current Rheumatology Reports?
Current Rheumatology Reports’ Journal Impact Factor is 4.9 (2025), and its 5-year Impact Factor is 5.7, according to Springer Nature’s published metrics.
Is Current Rheumatology Reports open access?
Current Rheumatology Reports is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 10 of 30 Current Rheumatology Reports articles (33%) carry a Creative Commons license, per Crossref.
Current Rheumatology Reports articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.
Start reading Current Rheumatology Reports today
One month free, then less than $2 a day. Current Rheumatology Reports, plus millions of articles from thousands of journals.




